Complex ABO Glycan Phenotypes Predicted by Lectin Microarrays
By LabMedica International staff writers Posted on 16 Sep 2020 |

Image: The LecChip and GlycoStation were used to identify subtle surface ABO blood group glycoprotein density variations (Photo courtesy of Glycotechnica).
Serological classification of individuals as A, B, O, or AB is a mainstay of blood banking. ABO blood groups or ABH antigens, in addition to other surface glycans, act as unique red blood cell (RBC) signatures and direct immune responses. ABO subgroups present as weakened, mixed field, or unexpected reactivity with serological reagents, but specific designations remain complex.
Lectins detect glycan motifs with some recognizing ABH antigens. Adaption of high-throughput microarrays spotted with a multitude of lectins, including lectins that recognize blood groups, may complement current methods for a more thorough interpretation of RBC ABH expression. Although many lectins have the ability to bind unique blood group antigens, few are tested for ABO-specific agglutination and, thus, limit their use in transfusion medicine.
Medical scientists at the Medical College of Wisconsin (Milwaukee, WI, USA) evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, using 20 samples for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology.
The total protein content from each extracted cell fraction was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The LecChip (Glycotechnica, Yokohama, Japan) was chosen as a testing platform because it provided a wide selection of lectins compared with other commercially available microarrays. Fluorescent microarray images were acquired using the Glycotechnica evanescent-field fluorescence scanner, GlycoStation Reader 2200. Samples were applied in a grid format to the membrane PVDF membranes for immunoblotting.
The team used principal component analysis and highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods.
The authors concluded that their study showed that ABH antigens on RBC glycoproteins were distinguishable by lectin array. Their analysis was limited to interrogating glycoproteins, but highlighted the importance of ABH localization on glycoproteins even within the same blood group. They identified changes associated with the expression of A and B antigens with increased levels of terminal and high mannose and branching polylactosamine. The study was published on August 21, 2020 in the journal Blood Advances.
Related Links:
Medical College of Wisconsin
Thermo Fisher Scientific
Glycotechnica
Lectins detect glycan motifs with some recognizing ABH antigens. Adaption of high-throughput microarrays spotted with a multitude of lectins, including lectins that recognize blood groups, may complement current methods for a more thorough interpretation of RBC ABH expression. Although many lectins have the ability to bind unique blood group antigens, few are tested for ABO-specific agglutination and, thus, limit their use in transfusion medicine.
Medical scientists at the Medical College of Wisconsin (Milwaukee, WI, USA) evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, using 20 samples for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology.
The total protein content from each extracted cell fraction was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The LecChip (Glycotechnica, Yokohama, Japan) was chosen as a testing platform because it provided a wide selection of lectins compared with other commercially available microarrays. Fluorescent microarray images were acquired using the Glycotechnica evanescent-field fluorescence scanner, GlycoStation Reader 2200. Samples were applied in a grid format to the membrane PVDF membranes for immunoblotting.
The team used principal component analysis and highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods.
The authors concluded that their study showed that ABH antigens on RBC glycoproteins were distinguishable by lectin array. Their analysis was limited to interrogating glycoproteins, but highlighted the importance of ABH localization on glycoproteins even within the same blood group. They identified changes associated with the expression of A and B antigens with increased levels of terminal and high mannose and branching polylactosamine. The study was published on August 21, 2020 in the journal Blood Advances.
Related Links:
Medical College of Wisconsin
Thermo Fisher Scientific
Glycotechnica
Latest Clinical Chem. News
- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
- Simple Urine Test Could Detect Multiple Cancers at Early Stage
- Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules
- First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns
- Paper-Based Devices Outperform Existing Methods in Diagnosing Asymptomatic Malaria
- Simple Skin Test Could Revolutionize Diagnosis of Pediatric Eosinophilic Esophagitis
- Portable Diagnostic Tool Uses Bioluminescence to Detect Viruses at POC
- AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Channels
Clinical Chemistry
view channel
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Opioid drugs such as fentanyl, morphine, and oxycodone are the primary substances associated with overdose cases in the United States. Standard drug screening procedures typically involve collecting blood,... Read moreMolecular Diagnostics
view channel
Genetic Test Could Predict Poor Outcomes in Lung Transplant Patients
Organ transplantation has dramatically transformed the management of patients suffering from organ failure. Yet, the immune system of the recipient often perceives the transplanted organ as a foreign entity,... Read more
Breakthrough Blood Test Enables Early Pancreatic Cancer Detection
Pancreatic cancer ranks as the fourth-leading cause of cancer-related deaths in the United States. At present, there are no molecular tools available for the early detection of this disease.... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Current tuberculosis (TB) tests face major limitations when it comes to accurately diagnosing the infection in individuals living with HIV. HIV, a frequent co-infection with TB, complicates detection by... Read more
Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota... Read more
Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
Urinary tract infections (UTIs) represent a massive burden on patients and healthcare systems. There are over 400 million UTI cases globally each year, of which around 90% are in women. Fast and accurate... Read more
POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read morePathology
view channel
AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. While saliva samples are used to perform genetic tests to determine, for example, paternity, the... Read moreTechnology
view channel
New Miniature Device to Transform Testing of Blood Cancer Treatments
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. However, despite its promise,... Read more
Biosensing Advancement to Enable Early Detection of Disease Biomarkers at POC
Traditional medical diagnostics often require clinical samples to be sent off-site, leading to time-consuming and costly processes. Point-of-care diagnostics offer a more efficient alternative, allowing... Read moreIndustry
view channel
AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. This deficiency is often linked... Read more